Claims for Patent: 9,931,330
✉ Email this page to a colleague
Summary for Patent: 9,931,330
Title: | Methods and devices for the treatment of ocular diseases in human subjects |
Abstract: | Methods and devices are provided for targeted non-surgical administration of a drug formulation to the suprachoroidal space (SCS) of the eye of a human subject for the treatment of a posterior ocular disorder or a choroidal malady. In one embodiment, the method comprises inserting a hollow microneedle into the eye at an insertion site and infusing a drug formulation through the inserted microneedle and into the suprachoroidal space of the eye, wherein the infused drug formulation flows within the suprachoroidal space away from the insertion site during the infusion. In one embodiment, the fluid drug formulation comprises drug nanoparticles or microparticles. |
Inventor(s): | Zarnitsyn; Vladimir (Atlanta, GA), Patel; Samirkumar (Atlanta, GA), White; Daniel (Suwanee, GA), Noronha; Glenn (Atlanta, GA), Burke; Brian (Cary, NC) |
Assignee: | CLEARSIDE BIOMEDICAL, INC. (Alpharetta, GA) |
Application Number: | 15/673,073 |
Patent Claims: | 1. A method of treating macular edema in a human subject in need thereof, the method comprising, non-surgically administering an effective amount of a drug formulation
comprising an anti-inflammatory drug to the suprachoroidal space (SCS) of the eye of the human subject in need of treatment of the macular edema; and further comprising non-surgically administering a second drug to the eye of the subject, wherein the
second drug comprises a vascular endothelial growth factor (VEGF) antagonist.
2. The method of claim 1, wherein the macular edema is diabetic macular edema. 3. The method of claim 1, wherein the VEGF antagonist is selected from a VEGF-receptor kinase antagonist, an anti-VEGF antibody or fragment thereof, an anti-VEGF receptor antibody, an anti-VEGF aptamer, a small molecule VEGF antagonist, a thiazolidinedione, a quinoline or a designed ankyrin repeat protein (DARPin). 4. The method of claim 1, wherein the VEGF antagonist is aflibercept. 5. The method of claim 1, wherein the anti-inflammatory drug is selected from mycophenolate, infliximab, nepafenac, azathioprine, cyclosphosphamide, dexamethasone, difluprednate, fluocinolone, fluorometholone, leteprednol, prednisolone acetate, prednisolone sodium phosphate, rimexolone, triamcinolone, bromfenac, diclofenac, fluibiprofen, ketorolac, adalimumab, etanercept, certolizumab, gotimumab, daclizumab, rituximab, abatacept, basiliximab, belimumab, anakinra, efalizuma, alefacept, and natalizumab. 6. The method of claim 1, wherein the anti-inflammatory drug is triamcinolone. 7. The method of claim 1, wherein the anti-inflammatory drug is triamcinolone acetonide. 8. The method of claim 1, wherein the second drug is administered to the suprachoroidal space (SCS) of the eye of the subject. 9. The method of claim 1, wherein the second drug is administered intravitreally in a second drug formulation. 10. The method of claim 1, wherein the first drug and second drug are administered to the subject in one dosing session. 11. The method of claim 1, wherein upon administration of the drug formulation to the SCS, the drug formulation flows away from the insertion site and is substantially localized to the posterior segment of the eye. 12. The method of claim 1, wherein the macular edema is macular edema secondary to retinal vein occlusion. |
Details for Patent 9,931,330
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | 11/26/1997 | ⤷ Try a Trial | 2032-11-08 |
Novartis Pharmaceuticals Corporation | SIMULECT | basiliximab | For Injection | 103764 | 05/12/1998 | ⤷ Try a Trial | 2032-11-08 |
Novartis Pharmaceuticals Corporation | SIMULECT | basiliximab | For Injection | 103764 | 01/02/2003 | ⤷ Try a Trial | 2032-11-08 |
Janssen Biotech, Inc. | REMICADE | infliximab | For Injection | 103772 | 08/24/1998 | ⤷ Try a Trial | 2032-11-08 |
Immunex Corporation | ENBREL | etanercept | For Injection | 103795 | 11/02/1998 | ⤷ Try a Trial | 2032-11-08 |
Immunex Corporation | ENBREL | etanercept | For Injection | 103795 | 05/27/1999 | ⤷ Try a Trial | 2032-11-08 |
Immunex Corporation | ENBREL | etanercept | Injection | 103795 | 09/27/2004 | ⤷ Try a Trial | 2032-11-08 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.